ONO-7119-01:Phase I study of ONO-7119 alone and in combination with ONO-4538 in patients with solid tumors

ONO-7119-01:A Phase I, open-label, uncontrolled, dose escalation and expansion study to evaluate the tolerability and safety of ONO-7119 alone and in combination with ONO-4538 in patients with unresectable advanced or recurrent solid tumors

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210373

Enrollment

Registered

2021-10-12

Start date

2021-11-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or recurrent solid tumor

Interventions

ONO-7119 is administered as a single agent or combination with ONO-4538.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient with advanced or recurrent solid tumor 2.Patients have an ECOG performance status of 0 to 1 3.Patients with a life expectancy of at least 3 months

Exclusion criteria

Exclusion criteria: 1.Patients are unable to swallow oral medications 2.Patients with severe complication

Design outcomes

Primary

Measure	Time frame
Safety and tolerability	—

Contacts

Public ContactMedical Center

Ono Pharmaceutical Co.,LTD

clinical_trial@ono-pharma.com+81-120626190

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026